Abstracts tagged "Malignancy"

Abstract Number: 585 • 2013 ACR/ARHP Annual Meeting
Breast Cancer In Systemic Lupus (SLE): Do Demographic and Clinical Factors, Including DNA serology, Influence Risk?
Sasha Bernatsky¹, Rosalind Ramsey-Goldman², Michelle Petri³, Murray B. Urowitz⁴, Dafna D. Gladman⁵, Christine Peschken⁶, William Foulkes¹, Yvan St. Pierre⁷, Patrice Chrétien Raymer⁷, Basile Tessier Cloutier⁸, Guillermo Ruiz-Irastorza⁹, Ann E. Clarke¹ and Systemic Lupus International Collaborating Clinics (SLICC)¹⁰, ¹McGill University, Montreal, QC, Canada, ²Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁶Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁷Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁸Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁹Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ¹⁰(coordinating centre), Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: There is an increase in cancer in SLE over-all, but decrease in other cancers, such as breast cancer. Of particular interest are autoantibodies targeting…
Abstract Number: 419 • 2013 ACR/ARHP Annual Meeting
A Long Term Observation Of Rheumatoid Arthritis Who Developed Methotrexate Related Lymphoproliferative Disorders
Yukiko Kamogawa¹, Kyohei Nakamura², Ryu Watanabe², Tsuyoshi Shirai¹, Yoko Fujita³, Yuko Shirota⁴, Noriko Fukuhara¹, Hiroshi Fujii², Shinichiro Saito⁵, Tomonori Ishii² and Hideo Harigae², ¹Tohoku University, Sendai, Japan, ²Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ³Department of Hematolgy and rheumatolgy, Tohoku University, Sendai, Japan, ⁴Department of Hematology and Rheumatolgy, Tohoku University, Sendai, Japan, ⁵Department of hematology and rheumatology, Tohoku University, Sendai, Japan
Background/Purpose: Methotrexate (MTX) has been increasingly administered by patients with rheumatoid arthritis (RA). In rare cases, we experience development of malignant lymphoma in patients treated…
Abstract Number: 224 • 2012 ACR/ARHP Annual Meeting
Standardized Incidence Ratios and Predictors of Malignancies in 215 Southern Chinese Patients with Inflammatory Myopathies
Chi Chiu Mok¹, Chi Hung To¹, ML Yip² and King Yee Ying³, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Division of Rheumatology, Department of Medicine, Kwong Wah Hospital, Kowloon, Hong Kong, ³Department of Medicine, Princess Margaret Hospital, Hong Kong, Hong Kong
Background/Purpose: To examine the standardized incidence ratios (SIRs) and predictive factors for malignancy in a cohort of southern Chinese patients with inflammatory myopathies (IM). Methods:…
Abstract Number: 707 • 2012 ACR/ARHP Annual Meeting
Risk of Cancer in Systemic Sclerosis: Meta-Analysis of Population-Based Cohort Studies
Akira Onishi¹, Daisuke Sugiyama², Akio Morinobu³ and Shunichi Kumagai⁴, ¹Rheumaology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Preventive Medicine and Public Health, School of Medicine, Keio University, Tokyo, Japan, ³Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Center of Rheumatic Diseases, Shinko Hospital, Kobe, Japan
Background/Purpose: The risk of cancer compared with general population has been elevated in several connective tissue diseases. However, the standardized incidence ratios (SIRs) for overall…
Abstract Number: 1593 • 2012 ACR/ARHP Annual Meeting
The Risk of Lymphoma in Patients Receiving Anti-Tumor Necrosis Factor Therapy for Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis
Louise K. Mercer¹, Mark Lunt², Audrey S. Low³, James B. Galloway², Kath Watson⁴, William G. Dixon⁵, BSRBR Control Centre Consortium², Deborah P. Symmons³, Kimme L. Hyrich⁶ and On behalf of the BSRBR⁷, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁵The University of Manchester, Manchester, United Kingdom, ⁶Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, ⁷British Society for Rheumatology, London, United Kingdom
Background/Purpose: The risk of lymphoma is increased in people with RA compared to the general population and is greatest in severe RA. Anti-TNF therapy is…